Possible Beneficial Effect of Dapagliflozin in Improvement of Dyspnea Scale (VAS and SA-NYHA Class) in Patients with Acute Decompensated Heart Failure (ADHF)
DOI:
https://doi.org/10.32792/utq/utjsci/v11i2.1274Keywords:
Dapagliflozin, Acute Decompensated Heart Failure, Dyspnea Scale, Visual Analog Scale, 5-point Likert scaleAbstract
Heart failure (HF) is a condition in which the heart is unable to pump enough blood to meet the body's needs. Diuretics are the mainstay of acute heart failure therapy, especially intravenous loop diuretics. In this study, IV.furosemide (120mg/day) plus 10mg dapagliflozin tablet were used daily. The aim of the present study is to observe the Possible beneficial effect of dapagliflozin in the improvement of dyspnea scale (VAS and SA-NYHA Class) in patients with ADHF. Between October 2023 and April 2024, a study was conducted at AL- Nasiriyah Heart Center, in the coronary care unit (CCU), in , southern of Iraq. One hundred subjects, both male and female were enrolled in the study after describing the study's goals, gauging patient satisfaction, and getting informed consent from the subjects. 100 enrolled patients were divided into two groups: The control group (Group A) involved (50 patients), given IV.furosemide (120mg/day) and the studied group (Group B) involved (50 patients), given IV. furosemide (120 mg/day) plus 10mg dapagliflozin tablet daily. Then, it was the assessment of symptoms of dyspnea by Visual Analog Scale and SA-NYHA class. It was found that dyspnea scales (VAS and SA-NYHA Class ) for patients in both groups (A and B) at hospital admission were significantly improved after subsequent days of admission.
Received: 2024-06-30
Revised: 2024-07-25
Accepted: 2024-08-08
References
[1] A. G. Bertoni, L. E. Wagenknecht, D. W. Kitzman, S. M. Marcovina, J. T. Rushing, M. A. Espeland,et al., "Impact of the look AHEAD intervention on NT‐pro brain natriuretic peptide in overweight and obese adults with diabetes," Obesity, 20(7), 1511-1518, 2012.
[2] C. W.Yancy, M. Jessup, B. Bozkurt, J. Butler, D. E. Casey, M. H. Drazner, et al., "2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines," Journal of the American college of cardiology, 62(16), e147-e239, 2013.
[3] S. V. Arnold, "Assessment of the patient with heart failure symptoms and risk factors: A guide for the non‐cardiologist," Diabetes, Obesity and Metabolism, 25, 15-25, 2023.
[4] S. Al-Hajj, S. H. Farran, A. M. Sibai, R. R. Hamadeh, V. Rahimi-Movaghar, R. M. Al-Raddadi, et al., "Injury burden in individuals aged 50 years or older in the Eastern Mediterranean region, 1990–2019: a systematic analysis from the Global Burden of Disease Study 2019," The Lancet Healthy Longevity, 3(4), e262-e1, 2022.
[5] B. C. Lampert, D. B. Dyke, & T. M. Koelling, "Heart failure due to left ventricular systolic dysfunction," Practical Cardiology: Evaluation and Treatment of Common Cardiovascular Disorders, 149-175, 2020.
[6] M. G. Del Buono, L. Buckley, & A. Abbate, "Primary and secondary diastolic dysfunction in heart failure with preserved ejection fraction," The American journal of cardiology, 122(9), 1578-1587, 2018.
[7] A. Lymperopoulos, N. Cora, J. Maning, A. R. Brill, & A. Sizova, "Signaling and function of cardiac autonomic nervous system receptors: Insights from the GPCR signalling universe," The FEBS Journal, 288(8), 2645-2659, 2021.
[8] A. Mebazaa, M. S. Nieminen, M. Packer, A. Cohen-Solal, F. X. Kleber, S. J. Pocock, et al., "Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial," Jama, 297(17), 1883-1891, 2007.
[9] L. Grosman-Rimon, F. Billia, E. Wright, S. Carasso, G. Elbaz-Greener, E. Kachel, et al., "Neurohormones, inflammatory mediators, and cardiovascular injury in the setting of heart failure," Heart Failure Reviews, 25, 685-701, 2020.
[10] R. L. Page, C. L. O’Bryant, D. Cheng, T. J. Dow, B. Ky, C. M. Stein, et al., "Drugs that may cause or exacerbate heart failure: a scientific statement from the American Heart Association," Circulation, 134(6), e32-e69, 2016.
[11] P. A. Heidenreich, B. Bozkurt, D. Aguilar, L. A. Allen, J. J. Byun, M. M. Colvin, et al., "2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines," Journal of the American College of Cardiology, 79(17), e263-e421, 2022.
[12] PS Pang, SP Collins, K. Sauser, A-C Andrei, AB Storrow, JE Hollander, et al., "Assessment of Dyspnea Early in Acute Heart Failure: Patient Characteristics and Response Differences Between Likert and Visual Analog Scales," Acad Emerg Med, 21(6):659–66, 2014.
[13] A. Mebazaa, PS. Pang, M. Tavares, SP. Collins, AB. Storrow, S. Laribi, et al., "The impact of early standard therapy on dyspnoea in patients with acute heart failure: the URGENT-dyspnoea study," Eur Heart J, 31(7):832–41, 2010.
[14] HA. Smithline, S. Caglar, & FSJ. Blank, "Physician vs patient assessment of dyspnea during acute decompensated heart failure," Congest Heart Fail, 16(2):60–4, 2010.
[15] M. Metra, P. Ponikowski, G. Cotter, BA. Davison, GM. Felker, & G. Filippatos, "Effects of serelaxin in subgroups of patients with acute heart failure: results from RELAX-AHF," Eur Heart J, 34(40):3128–36, 2013.
[16] S. Linko, "Automated ion-selective measurement of lithium in serum. A practical approach to result-level verification in a two-way method validation," Validation in Chemical Measurement, 101-106, 2005.
[17] C. Kara Genoglu, A. Kose, S. Bozkurt Babuş, I. Toker, S. Erdogan, N. Muşlu, et al., "Assessment of Dyspnea in Acute Heart Failure Patients with Three Scales in the Emergency Department," Anatolian J Emerg Med, March,6(1):1-6, 2023.
[18] J. A. Bennett, B. Riegel, V. Bittner, & J. Nichols, "Validity and reliability of the NYHA classes for measuring research outcomes in patients with cardiac disease," Heart & Lung, 31(4), 262-270, 2002.
[19] R. D. S. Watson, C. R. Gibbs, & G. Y. H. Lip, "Clinical features and complications," Bmj, 320(7229), 236-239, 2000.
[20] J. A. Davidson, "SGLT2 inhibitors in patients with type 2 diabetes and renal disease: overview of current evidence," Postgraduate medicine, 131(4), 251-260, 2019.
[21] M. Shimizu, K. Suzuki, K. Kato, T. Jojima, T. Iijima, T. Murohisa, et al., "Evaluation of the effects of dapagliflozin, a sodium‐glucose co‐transporter‐2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non‐alcoholic fatty liver disease," Diabetes, Obesity and Metabolism, 21(2), 285-292, 2019.
[22] E. A. Wehrwein, & M. J. Joyner, "Regulation of blood pressure by the arterial baroreflex and autonomic nervous system," Handbook of Clinical Neurology, 117, 89-102, 2013.
[23] M. C. Petrie, S. Verma, K. F. Docherty, S. E. Inzucchi, I. Anand, J. Bělohlávek, et al., "Effect of dapagliflozin on worsening heart failure and cardiovascular death in patients with heart failure with and without diabetes," Jama, 323(14), 1353-1368, 2020.
Downloads
Published
License
Copyright (c) 2024 University of Thi-Qar Journal of Science
This work is licensed under a Creative Commons Attribution 4.0 International License.
